---
title: "Minzasolmin: Parkinson's Drug Pipeline"
description: "An oral drug aimed at preventing alpha-synuclein from clumping, in a Phase 2 trial. Whether it slows Parkinson's is not yet known."
canonical_url: "https://parkinsonspathways.com/pipeline/minzasolmin"
development_stage: "Phase 2: mid-stage testing"
last_updated: 2026-06-01
source: "Parkinson's Pathways"
---
# Minzasolmin

**Stage:** Phase 2 (ORCHESTRA)  ·  **Type:** Disease-modifying

**Developer:** UCB and Novartis

**How it works:** A pill designed to stop the alpha-synuclein protein from misfolding and clumping inside brain cells.

**Target:** Alpha-synuclein

**Who it's for:** People with early, untreated or recently treated Parkinson's.

**Key trials:** NCT04658186

**Last reviewed:** 2026-06-01


## What it is

Unlike antibody infusions that target alpha-synuclein from outside the cell, minzasolmin is a small molecule pill intended to interfere with the protein misfolding earlier in the process, inside the cell.

## Where it stands

It has been tested in the Phase 2 ORCHESTRA trial. Results determine whether the approach moves forward.

## What the data shows so far

ORCHESTRA enrolled people with early Parkinson's for roughly a year and a half, measuring change on Parkinson's rating scales. As with other disease-modifying attempts, any benefit would be a slowing of decline rather than immediate symptom relief; read-outs should be judged against the pre-specified primary endpoint, not selected subgroups.

## What families should know

This is another shot at the central alpha-synuclein hypothesis, in convenient pill form. It is experimental and not shown to slow the disease.

## Caveats

Unproven; a single Phase 2 study. The alpha-synuclein strategy as a whole has produced repeated disappointments, so cautious expectations are warranted.

## Timeline

_Most recent first._

- **2021**, ORCHESTRA Phase 2 trial begins.

## Sources

- [ORCHESTRA on ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04658186)

_Last reviewed: 2026-06-01._

## More

- [Back to the Parkinson's drug pipeline](https://parkinsonspathways.com/pipeline)
- [Browse all recruiting trials](https://parkinsonspathways.com/trials)